Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Soleno Therapeutics, Inc.
Age
4–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)
2. Participant must:
1. Have participated in and completed the Study C602 Randomized Withdrawal (RW) Period;
2. Have participated in but discontinued from the Study C602 RW Period and at least 16 weeks have elapsed since the date of their randomization into the C602 RW Period; or
3. Have participated in Study C602 OLE period, did not consent to participate in the RW Period, and at least 16 weeks have elapsed since the date of their C602 Open-Label Extension End of Treatment Visit.
You may not be if
1. Positive urine pregnancy test (in females of child-bearing potential)
2. Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation.
3. Participation in a clinical study of an investigational drug (including approved drugs for unapproved uses), investigational device, or therapeutic intervention subsequent to the C602 Open-Label Extension End of Treatment Visit.
Clareo Health | Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
